A Single-Center, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating Study to Evaluate the Safety and Tolerability of KDF-07002 in Healthy, Adult Volunteers

This is an early-stage (Phase 1) safety study testing a new investigational drug called KDF-07002 in healthy adult male volunteers. The purpose is to find out how safe and well-tolerated the drug is when given as a single intravenous (into a vein) dose, and to understand how the body processes it. Different groups of participants will each receive a progressively higher dose. Safety will be monitored closely for 7 days after the dose. You may be eligible if: - You are a male between 18 and 60 years old - You are in good general health with no significant medical conditions - You have easy-to-access veins for blood draws and injections - You agree to use reliable contraception if sexually active during the study and for 30 days after You may NOT be eligible if: - You have a known sensitivity to imaging contrast agents - You use illicit drugs or are alcohol-dependent - You have participated in another drug study in the past 30 days - You have donated blood in the past 30 days or had major surgery or injury in the past 45 days - You have epilepsy, seizures, anaemia, asthma, COPD, liver or kidney disease, or a bleeding disorder - You have had your spleen removed or have a history of pancreatitis - You take warfarin (a blood thinner) - You have an allergy to eggs Talk to your doctor about whether this trial might be right for you.